VEGF-A

CAT: 0209-101-MBi56Size: 50 µgDry Ice: NoHazardous: No
CAT#:0209-101-MBi56Size:50 µg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165) . All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.
Synonyms
VEGFA; VPF; VEGF; MVCD1
NCBI Gene ID
7422
UniProt
P15692
Accession Number
NP_001165097
Accession Number mRNA
NM_001171626
Chromosomal Location
6p12
Reactivity
Anti-Human
Cross Reactivity
Human
Target Antigen
Recombinant human VEGF165 (RT# 300-036)
Clone
(#3C5)
Label
Biotin
Applications
ELISA, WB
Purification Method
Protein G chromatography
Assay Protocol
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Bioactivity
ELISA: Use at 1-5 µg/ml; Western blotting: Use at 1-5 µg/ml.
Form
Lyophilized
Buffer
PBS
Reconstitution
Water
Storage Conditions
The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
Host or Source
Mouse
Isotype
IgG1

Related Products

CatalogName
M60-198-L100VEGFA / VEGF164 Protein
101-MBi34VEGFR-2/KDR
102-PA18VEGFR-2/KDR
101-MBi20VEGFR-2/KDR
102-PA18SVEGFR-2/KDR
101-MBi32VEGFR-2/KDR
M60-198-L1000VEGFA / VEGF164 Protein
101-M34VEGFR-2/KDR
101-M22VEGFR-2/KDR
101-MBi22VEGFR-2/KDR

Alternative Products

CatalogName
397209VEGF-A (VPF, VEGF)
CVR-0011-01VEGF (RBT-VEGF), RMab
33-479VEGF Antibody [VEGF/1063]
544429VEGF
405508-01VEGF-A

Popular Products